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Aim: This observational study with tiotropium Respimat® was performed in a real-life setting 
to investigate its effectiveness with regard to physical functioning and tolerability.
Methods: Patients with chronic obstructive pulmonary disease (COPD; n = 1,230; mean age, 
65.5 years) received tiotropium 5 µg once daily via Respimat® Soft Inhaler for 6 weeks in an 
open-label observational study. At baseline and week 6, patients completed the Physical Function 
subdomain [PF-10] of the Short Form (SF) 36 questionnaire.
Results: Improvement in standardized PF-10 score of 10 points was achieved by 61.5% of 
patients. Mean (SD) standardized PF-10 scores improved by 13.4 (15.9) points, from 49.0 (24.5) 
to 62.3 points (23.5; P < 0.001). Results in smokers (n = 435) were not significantly different to 
those in nonsmokers. The general condition of patients improved during treatment. Adverse events 
were reported by 4.0% of patients and were chiefly respiratory symptoms and dry mouth.
Conclusion: In COPD patients receiving tiotropium Respimat® in daily practice, physical 
function improved rapidly within 6 weeks of treatment, irrespective of smoking status.
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Introduction
Assessment of disease severity in patients with chronic obstructive pulmonary 
  disease (COPD) centers on measures of airflow limitation, such as forced   expiratory 
volume.1 However, patients with COPD also suffer considerably with extrapul-
monary effects of the disease, notably a loss of skeletal muscle mass (cachexia), 
which in tandem with poor pulmonary function, results in reduced physical activity.2 
Cardiovascular disorders and depression, also common in COPD patients,3 place 
further constraints on physical function, the deterioration of which contributes to 
the decline in the patient’s health status and quality of life.
In controlled trials in COPD patients, treatment with the inhaled long-acting 
  anticholinergic tiotropium (Spiriva®) not only improved lung function and 
  symptoms, and prevented exacerbations, but also improved health-related quality 
of life (HRQoL).4–8 The instrument used to measure HRQoL in these studies was 
the St George’s Respiratory Questionnaire (SGRQ),9 but in two of the studies,4,5 an 
additional measure was used, ie, the Short Form (SF)-36 questionnaire. The SF-36 
is a general instrument for measuring health status and is not aligned to any specific 
disease or patient population,10–12 and selected subdomains of this questionnaire, 
including the 10-item Physical Function Questionnaire (PF-10), have been shown to 
perform just as reliably when administered separately as when administered as part 
of the entire instrument.13 The PF-10 score constitutes a validated patient-relevant International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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measure of physical activity in daily living that can be easy 
applied in day-to-day clinical practice.14
The type of COPD patients who participate in observa-
tional studies often differ from those in randomized controlled 
clinical trials where more rigorous exclusion and inclusion 
criteria are defined. Observational studies performed in 
routine clinical practice provide more realistic evidence as 
to how a treatment will perform in a general clinical set-
ting. As a consequence, the results from these studies may 
have a greater external validity than randomized controlled 
clinical trials.15 In addition it should be noted that neither 
specific diagnostic nor therapeutic interventions are allowed 
in these trials. Noninterventional studies can provide addi-
tional information about the efficacy and safety of already 
registered drugs. The aim of this noninterventional trial with 
tiotropium Respimat® was to use the PF-10 questionnaire 
to measure changes in physical functioning of smokers and 
nonsmokers with COPD in everyday practice. Respimat, a 
multidose propellant-free active inhalation device, generates 
a fine, slow-moving cloud with a high fine particle fraction.16 
We also sought to assess the tolerability of treatment in these 
patients.
Methods
study design
This noninterventional study employed a prospective 
design, in which patients received treatment with tiotro-
pium   Respimat for approximately six weeks. Patients 
were enrolled by 230 office-based pulmonologists in 
Germany. The study was conducted according to the Ger-
man Medicines Act (Article 4, Section 23 and Article 67, 
Section 6), with the approval of the Baden-Württemberg 
Medical Association Ethics Committee and notified to the 
national authorities. All patients gave informed consent to 
participate.
Patients and treatments
Patients with a diagnosis of COPD who had not been treated 
with tiotropium in the six weeks before baseline and who 
required treatment with a long-acting bronchodilator were 
eligible for inclusion in the study.
At the first clinic visit, data were collected on demographics, 
smoking history, coexisting diseases, and current medica-
tions. All eligible patients started treatment with tiotropium 
5 µg once daily (two puffs of 2.5 µg) via the Respimat inhaler. 
Throughout the study period, patients were allowed to take 
any other pulmonary medications. After six weeks of study 
treatment, patients returned for a second clinic visit.
Assessments and endpoints
At baseline and week 6, physical function was measured by 
the 10 self-administered questions in the PF-10 of the SF-36 
questionnaire. The PF-10 questionnaire relates to whether 
patients are restricted in the following activities:
•	 Vigorous activities (eg, running, lifting heavy objects)
•	 Moderate activities (eg, moving a table, bowling)
•	 Lifting or carrying groceries
•	 Climbing several flights of stairs
•	 Climbing one flight of stairs
•	 Bending, kneeling, or stooping
•	 Walking more than one kilometer
•	 Walking several hundred meters
•	 Walking one hundred meters
•	 Bathing or dressing yourself
The sum of scores for the 10 items was standardized to 
a range of 0–100 points for analysis. The primary efficacy 
  endpoint was the proportion of patients achieving   “therapeutic 
success”, which was defined as a 10-point increase in the stan-
dardized PF-10 score between baseline and week 6. Adop-
tion of this threshold score of a 10-point change in minimal 
important difference (MID)  was based on a distribution-
based method by Cohen.17 Based on two one-year studies 
conducted in COPD patients,4 the baseline standard devia-
tion (SD) for Physical Functioning scores was 22. The MID 
ranged between 4.4 and 11.
Three secondary efficacy endpoints were also defined, 
ie, the absolute change in standardized PF-10 score from 
baseline to week 6, the change from baseline to week 6 in the 
Physician’s Global Evaluation (PGE) score, ie, the physician’s 
assessment of the patient’s general condition using an 
eight-point scale, and, finally, patient   satisfaction with 
tiotropium Respimat, measured at week 6 only.   Satisfaction 
was measured using a seven-point ordinal scale from “very 
dissatisfied” to “very satisfied”.
Tolerability was assessed by investigators at the week 6 
visit, by documenting all adverse events that had occurred 
during the study treatment period.
statistical analysis
All patients in the treated set (any patients who received at 
least one dose of tiotropium Respimat) were analyzed for 
tolerability. Patients in the treated set who had a diagnosis 
of COPD constituted the full analysis set, which was used 
for analysis of PGE and satisfaction results. For the primary 
efficacy endpoint, results were analyzed for the efficacy set, 
ie, all those in the full analysis set for whom PF-10 values at 
baseline and week 6 were available. For all efficacy measures, International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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Table 1 Patient demographics and characteristics at baseline
Parameter Parameter value (mean and 
SD unless stated)
Treated and full 
analysis sets
Efficacy set
number of patients 1280 1230
Men (n, %) 780 (60.9%) 755 (61.4%)
Age (years) 65.5 (10.6) 65.5 (10.5)
Time since initial diagnosis (years) 7.5 (7.3) 7.5 (7.3)
smoking status (n, %)
  smokers 454 (35.5%) 435 (35.4%)
  exsmokers 616 (48.1%) 594 (48.3%)
  never-smokers 210 (16.4%) 201 (16.3%)
Pack-years (smokers) 39.9 (32.3) 39.1 (32.0)
Pack-years (exsmokers) 33.0 (18.1)  33.0 (18.2)
Notes: Treated set = patients who received at least one dose of tiotropium Respimat®; 
full analysis set = patients in the treated set with a diagnosis of COPD; efficacy set = 
patients in the full analysis set with a PF-10 value at baseline and at week 6. 
Abbreviations: sD, standard deviation; COPD, chronic obstructive pulmonary 
disease.
Table 2 Absolute values of standardized PF-10 score at baseline 
and week 6 in efficacy set (n = 1230)
Mean PF-10 score (SD)
All patients (n = 1230) 49.0 (24.5)
Baseline 62.3 (23.5)
Week 6 13.4 (15.9)
Difference (week 6 minus baseline) ,0.001
P value for the difference*
smokers (n = 435)
Baseline 52.4 (24.8)
Week 6 65.0 (22.9)
Difference (week 6 minus baseline) 12.7 (15.8)
P value for the difference* ,0.001
nonsmokers (n = 795)
Baseline 47.1 (24.1)
Week 6 60.8 (23.8)
Difference (week 6 minus baseline) 13.7 (15.9)
P value for the difference* ,0.001
Note: *Wilcoxon signed rank test.
results were also analyzed in two patient subgroups, ie, 
  smokers and nonsmokers. The group of nonsmokers com-
prised exsmokers and never-smokers.
Descriptive statistics including differences from 
  baseline were prepared for the standardized PF-10 score, 
for all patients and for the smoker and nonsmoker 
subgroups.
Differences between the subgroups in therapeutic suc-
cess rates (measured by PF-10 scores) were analyzed using 
the Cochran–Mantel–Haenszel test, and the Wilcoxon 
signed rank test was used to analyze the difference between 
the absolute PF-10 scores at baseline and those at week 6. 
A least squares mean analysis was performed for the changes 
from baseline in PF-10 scores and comparison of these scores 
between subgroups (by smoking status); this analysis was 
adjusted for baseline PF-10 score and for region (federal 
state). For estimated therapeutic success rates, 95% confi-
dence intervals (CI) were calculated. P values of , 0.05 were 
considered statistically significant.
Results
Patient disposition
A total of 1280 patients were enrolled from 230 centers. These 
formed the treated set that was used for the safety analysis. 
Because all patients in the treated set had a diagnosis of 
COPD, the full analysis set (used for all efficacy analyses 
other than the PF-10 endpoint) was also 1280 patients. Data 
on PF-10 were missing for 50 of the patients in the full 
analysis set, so the efficacy set consisted of 1230 patients. 
  Fifty-seven of 1280 patients withdrew from the study 
prematurely, 36 because of adverse events and 21 for other 
reasons.
The baseline characteristics and demographic profiles of 
the full analysis set and efficacy set are shown in Table 1. 
More men than women were enrolled, the mean age of the 
sample was 65.5 years, and the mean duration of COPD 
was 7.5 years. Just over one-third of the patients (35.5%) 
were current smokers; 59.9% of smokers and 61.5% of 
nonsmokers were male patients. Mean age of smokers and 
nonsmokers was 61.0 (± 10.4) years and 68.0 (±9.8) years, 
respectively.
In addition to COPD, 71.8% (919) of patients had 
other diseases, most commonly cardiac in nature (44.5%, 
n = 569). Vascular disorders and metabolic or endocrine 
disorders were also prevalent, affecting 22.3% (285) and 
18.8% (241) of patients, respectively, and 11.8% (151) of 
patients had   additional pulmonary disorders. Pulmonary 
comedications were being taken by 83.5% of patients in 
the full analysis set and 84.1% of the efficacy set. The most 
common of these were short-acting beta-agonists (54.9%), 
long-acting beta-agonists either alone (32.0%) or combined 
with inhaled corticosteroids (26.5%), inhaled corticosteroids 
alone (21.8%), and theophylline (17.4%).
Efficacy
Physical function
For the primary efficacy endpoint, ie, improvement in the 
PF-10 score, 61.5% of the patients in the efficacy set achieved 
“therapeutic success” (95% CI: 58.8%–64.3%). There was no 
statistically significant difference in the success rate between International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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Figure 1 Distribution of Physicians’ global evaluation scores for all patients in the full analysis set (n = 1280) at baseline and week 6.
smokers (61.4%; 95% CI: 56.6%–66.0%) and nonsmokers 
(61.6%; 95% CI: 58.2%–65.0%; P = 0.93 for difference).
Absolute changes in PF-10 subdomain scores after 
six weeks are shown in Table 2. Mean scores for all 
patients improved from 49.0 points (SD, 24.5) at baseline 
to 62.3 (23.5) points at week 6, giving a mean difference 
of 13.4 points (15.9) that was statistically significant 
(P , 0.001) and exceeded the minimal important difference 
of 10 points. Mean score improvements from baseline were 
also statistically significant in both smoking subgroups 
(P , 0.001), despite a significantly higher mean baseline 
PF-10 score in smokers (52.4; 95% CI: 50.0–54.7) than in 
nonsmokers (47.1; 95% CI: 45.4–48.8). The mean score 
improvements in both subgroups, from 52.4 to 65.0 in 
smokers and from 47.1 to 60.8 in nonsmokers, exceeded the 
MID of 10 points, and least squares mean analysis showed 
no significant difference between subgroups in the change 
from baseline to week 6.
Other efficacy endpoints
The change in PGE scores from baseline to week 6 showed 
an improvement in patients’ general condition during the 
study (Figure 1). The proportion of patients rated as poor 
(score of 1 or 2) fell from 16.2% (207) to 3.0% (39) and the 
proportion with a rating of good (score of 5 or 6) more than 
doubled, from 23.0% (294) to 54.6% (699). The pattern of 
results in smokers was very similar to that in nonsmokers 
(data not shown).
At week 6, 76.9% (984) of patients rated their level of 
satisfaction with the inhalation device as “satisfied” or “very 
satisfied” (Figure 2). The ratings in smokers were very similar 
to those in nonsmokers (data not shown).
safety
Patients were exposed to tiotropium for a mean of 47.6 days 
(SD, 15.2 days), the median exposure being 44 days. Fifty-one 
of 1280 patients in the treated set (4.0%) reported adverse 
events during the study and 36 patients (2.8%) discontinued 
study treatment because of adverse events. Twenty-seven 
patients (2.1%) experienced adverse events that were judged 
to be related to study medication. On the whole, the events 
fell into one of two groups, either continuing symptoms and 
signs of COPD, such as cough, dyspnea, and chest infections, 
or typical anticholinergic side effects, such as dry mouth 
(the most common single event, observed in 11 patients) 
and tachycardia (observed in 3 patients). Five patients each 
reported dizziness and headache. All reported events are 
listed by system organ class in Table 3.
In all, 16 serious adverse events were reported by 
six (0.5%) patients. Six of these events occurred in one 
patient (benign prostatic hypertrophy, urinary tract infection 
with urinary retention, constipation, azotemia, and transient 
collapse). At the time of the last recorded contact with the International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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Figure 2 Ratings of patient satisfaction with the inhalation device (Respimat® soft Mist Inhaler) at week 6; full analysis set (n = 1280).
Abbreviation: “neither/nor”, neither satisfied nor dissatisfied.
patient, the patient had recovered from the collapse except 
for the urinary tract events. No deaths occurred during the 
study.
Discussion
The present study is the first observational study that 
investigates the effect of tiotropium Respimat on physical 
activity in a large patient population in primary care. We 
showed that PF-10 represents a valid and feasible measure 
of physical activity in daily living. This is in contrast with 
other more complex instruments, such as SGRQ, which are 
of limited use in day-to-day clinical practice.
The majority (61.5%) of patients who received a once-daily 
dose of tiotropium Respimat for six weeks achieved therapeu-
tic success, as measured by an increase in the standardized 
PF-10 score of at least 10 points. Results for the other efficacy 
measures supported the primary endpoint findings. Physical 
function improved overall during the six-week study period, 
as shown by a significant increase in the mean standardized 
PF-10 score of 13.4 points. In addition, the improvement in 
the distribution of PGE scores at week 6 for all participants 
showed that patients were generally in a healthier condition 
than at baseline. The improvement in PF-10 scores that we 
recorded is similar to the results of two other observational 
studies of tiotropium in the HandiHaler® at a daily dose of 
18 µg;18,19 PF-10 increased by 13.3 and 15.8 points, respec-
tively, and PGE scores improved from baseline.
Patient-reported outcomes have been studied in previous 
clinical trials of tiotropium, usually with the SGRQ, a specific 
measure of health status for patients with obstructive lung 
disease.9 The SF-36 questionnaire, of which the PF-10 is the 
largest individual subdomain, is a general health status measure 
which is used less frequently than SGRQ in studies of patients 
with COPD. Nevertheless, a pooled analysis of two one-year 
studies of tiotropium by Casaburi et al used both SGRQ and 
SF-36 to assess health status and found that mean scores for the 
physical health subdomains, including physical function, were 
significantly better for tiotropium than placebo throughout 
the study.4 Another similar combined analysis of two studies 
reported by Vincken et al found that after one year’s treatment, 
tiotropium was associated with significantly higher scores 
than ipratropium for some physical health subdomains of the 
SF-36 but the authors did not state how much SF-36 scores 
had improved between baseline and the end of the trial.5
The safety profile of tiotropium in this observational 
study was consistent with accumulated clinical trial 
experience.20,21 In all, only 4% of patients reported adverse 
events, although this result reflects the less stringent report-
ing   procedures for adverse events in observational studies 
  compared with a randomized clinical trial.4,22 Because it was 
a short-term six-week observational study, no conclusions 
can be made on any long-term adverse events.
When analyzed by subgroup, our results showed that 
both smokers and nonsmokers experienced physical function International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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Table  3  number  of  patients  in  the  treated  set  (n  =  1280) 
reporting adverse events, by system organ class*
Number of patients reporting 
events (% of treated set)
number of patients reporting any  
adverse event 
51 (4.0)
Respiratory, thoracic, and  
mediastinal disorders
17 (1.3)
  Cough 10 (0.8)
  Dyspnea 5 (0.4)
  Throat irritation 2 (0.2)
gastrointestinal disorders 16 (1.3)
  Dry mouth 11 (0.9)
  Dyspepsia 2 (0.2)
nervous system disorders 11 (0.9)
  Dizziness 5 (0.4)
  headache 5 (0.4)
Infections and infestations 9 (0.7)
  Bronchitis 2 (0.2)
  Infection 2 (0.2)
  Infective exacerbation of COPD 2 (0.2)
  Urinary tract infection  2 (0.2)
Cardiac disorders 5 (0.4)
  Tachycardia 3 (0.2)
general disorders and  
administration site conditions
5 (0.4)
  Chest discomfort 3 (0.2)
Renal and urinary disorders 3 (0.2)
  Urinary retention 2 (0.2)
neoplasms benign, malignant,  
and unspecified
2 (0.2)
skin and subcutaneous  
tissue disorders
2 (0.2)
Vascular disorders 2 (0.2)
Notes: *Table contains serious and nonserious adverse events. Within each system 
organ class, events are also listed by preferred term if reported by two or more 
patients. 
Abbreviation: COPD, chronic obstructive pulmonary disease.
improvements with tiotropium therapy, with no significant 
differences in treatment responses between these two subgroups 
either in the proportion who achieved therapeutic success or 
the absolute change in PF-10 scores from baseline. This result 
was remarkable, given that mean baseline PF-10 scores were 
significantly higher in smokers than nonsmokers. This difference 
in subgroups at baseline could have been due to a difference 
in COPD severity, ie, GOLD (Global Initiative for Chronic 
Obstructive Lung Disease) stage between the two treatment 
groups. In addition, smokers were of younger age compared with 
nonsmokers (median ages 61 and 68 years, respectively).
Another outcome assessed in this study was satisfaction with 
the inhalation device. Approximately 77% of the participants 
were either satisfied or very satisfied with the Respimat inhaler, 
and 4.2% in total reported some level of dissatisfaction (from 
“rather dissatisfied” to “very dissatisfied”). These findings are 
consistent with results of controlled clinical trials that have 
measured patient satisfaction with the Respimat inhaler using 
a validated questionnaire specific for inhalation devices.23,24
Our study had some limitations. The patients in this 
noninterventional, open-label, nonrandomized, observational 
study were relatively unselected compared with those typically 
enrolled into randomized controlled trials; entry to the 
study required a diagnosis of COPD, the need for treatment 
with a long-acting bronchodilator, and no treatment with 
tiotropium in the preceding six weeks. Although the benefits in 
physical functioning were not confirmed by assessing exercise 
capacity with, for example, the six-minute walk test, the lack 
of patient selection allows our findings to be more readily 
generalized to a real-life setting, in which COPD patients have 
a wide range of comorbidities. Another possible limitation 
was the short duration of our study. Whether improvement of 
physical functioning can be maintained over a longer period 
of time needs further clarification. In addition, this study was 
neither designed nor powered to study the potential impact of 
comedication on the results of this study.
Strengths of this noninterventional study include the 
large patient sample size, the high number of participating 
  physicians and inclusion of patients with coexisting   diseases 
and a wide spectrum of disease severity and treatment 
tailored to the individual patient. By contrast, randomized 
clinical trials usually have a distinct group of patients as a 
result of specific exclusion and inclusion criteria regarding 
concomitant diseases and therapy, and the study protocol may 
not be representative of clinical practice.25 Accordingly, this 
observational study includes typical COPD patients from a 
real life primary care setting and reflects current treatment 
approaches, thus complementing the findings of randomized 
controlled trials. In summary, this observational study showed 
that treatment with inhaled tiotropium administered via 
Respimat inhaler was associated with rapid improvements in 
physical functioning in COPD patients in a real-life setting, 
irrespective of smoking status.
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